Changes in Metastatic Castration Sensitive Prostate Cancer

Gurbuz M., ÜRÜN Y.

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, cilt.20, sa.1, ss.1-6, 2021 (ESCI) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 20 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4274/uob.galenos.2019.1407
  • Dergi Adı: UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-6
  • Anahtar Kelimeler: Prostate cancer, castration sensitive, treatment, chemotherapy, CYPROTERONE-ACETATE, THERAPY, DOCETAXEL, MITOXANTRONE, PREDNISONE, MEN
  • Ankara Üniversitesi Adresli: Evet

Özet

Prostate cancer is the second most common cancer in men worldwide, with approximately 1,276,106 new patients and 358,989 new deaths. Metastatic castration-sensitive prostate cancer may be de novo metastatic, but also it may be in the localized disease stage at the time of diagnosis, and may present as biochemical relapse and later metastatic disease over time. Purposes of metastatic castration-sensitive prostate cancer treatment are prolonging survival, improving quality of life and reducing complications. In this review, it is aimed to evaluate the current developments in metastatic castration-sensitive prostate cancer treatment.